Table 1: The general information and laboratory data of the new diagnosed metabolic syndrome patients at the baseline and 12 weeks after the therapy.

Before medicationAfter medication value

Participants (M/F)37 (17/20)37 (17/20)
Age (years)
Body mass index (kg/m2) <0.01
Waist circumference (cm) 0.04
Systolic pressure (mmHg) 0.32
Diastolic pressure (mmHg) 0.24
Total cholesterol (mM) 0.03
High-density lipoprotein cholesterol (mM) 0.06
Low-density lipoprotein cholesterol (mM) 0.03
Triglyceride (mM) <0.01
Fasting plasma glucose (mM) 0.03
HbA1c (%) 0.02
Leptin (ug/L)8.01 (2.04~15.17)5.12 (1.88~12.89)0.04
Adiponectin (mg/L)8.42 (4.75~14.81)10.02 (5.13~15.59)0.14
Leptin/adiponectin0.76 (0.29~2.85)0.58 (0.14~1.22)0.02
Fasting insulin (mIU/L)16.90 (11.6~20.1)12.50 (9.7~14.8)0.04
HOMA-IR5.46 (3.62~6.69)3.25 (2.50~4.58)0.03
Glutamic-pyruvic transaminase (U/L) 0.62
γ-Glutamyl transpeptidase (U/L) 0.74
Creatinine (mM) 0.77

t-test of paired measurement data comparisons between two comparing lines before and after medication. Data of nonnormal distribution were described using the median (M) and quartile (Q1~Q4).